1. Sotatercept significantly reduced serious clinical events among high-risk patients with pulmonary arterial hypertension (PAH).
2. The phase III trial investigated sotatercept in patients with WHO functional class III or IV PAH and a REVEAL Lite 2 risk score of nine or greater.
3. The primary end point measured time to lung transplantation, hospitalization due to worsening PAH, or death.
4. Sotatercept reduced the risk of major clinical outcomes in patients at high risk for death when added to background therapy.

Source: The New England Journal of Medicine